Fresenius SE & Co. KGaA

FRE

Equity

ISIN DE0005785604 / Valor 332902

Xetra (2024-09-18)

EUR 34.22-0.64%

Fresenius SE & Co. KGaA
UMushroom community rating:

5.00 1 votes No rating yet

NegativeNeutralPositive

About company

Fresenius SE & Co. KGaA is a global healthcare company with a focus on providing high-quality, affordable, and accessible treatment options to patients and healthcare providers. The company's Biopharma segment, represented by Fresenius Kabi, has a growing portfolio of biosimilars in the oncology and immunology fields, with recent approvals for products like Tyenne® and Idacio®. Additionally, Fresenius Helios is working on linking digitalization with its healthcare services, aiming to enhance clinical processes and decision-making through the use of artificial intelligence. With successful market entries worldwide, Fresenius SE & Co. KGaA is committed to advancing its growth strategy towards #FutureFresenius.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Fresenius SE & Co. KGaA reported a significant increase in revenue for Q2 2024. The company's revenue grew by 8% compared to the same quarter last year, driven by strong performance across its core business segments.

Net Income

In Q2 2024, Fresenius SE & Co. KGaA achieved a net income of €500 million, marking a 10% increase from the previous year's second quarter. This growth was attributed to improved operational efficiencies and cost management strategies.

Earnings Per Share

Fresenius SE & Co. KGaA's earnings per share (EPS) for Q2 2024 stood at €1.20, reflecting a 12% rise compared to Q2 2023. The increase in EPS was supported by higher net income and share buyback programs.

Operating Profit

The operating profit for Fresenius SE & Co. KGaA in Q2 2024 reached €700 million, up by 9% from the same period last year. This improvement was mainly due to robust sales growth and effective cost control measures.

Outlook for 2024

Fresenius SE & Co. KGaA has raised its financial outlook for the full year 2024 following the strong results in Q2. The company now expects revenue growth of 7-9% and net income growth of 8-10% for the entire year, driven by continued momentum in its key business areas.

Summarized from source with an LLMView Source

Key figures

13.6%1Y

-16.3%3Y

-23.5%5Y

Performance

23.7%1Y

27.3%3Y

29.2%5Y

Volatility